BioVolume is the world’s first 3D imaging solution that has been developed in partnership with a leading pharmaceutical company and wider industry for visualising and measuring subcutaneous tumour growth in preclinical oncology research.
It was conceived to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics.
Used by leading pharma, biotech and research institutions including:
“After purchasing the unit, it is now being used daily scanning on average 6 different protocols, saving us 30-60 minutes every day. BioVolume has lessened the error in tumor measurement and it has helped significantly in recognizing when the tumor has fully taken to the mouse rather than it being Matrigel.”
Emily McLure, Research Associate II/ Research Animal Lab Manager, Orano med
BioVolume enables cancer research companies to obtain more accurate, repeatable data than before. Translational science is also improved through data reliability and transparency.
By significantly reducing
inter-operator variability across studies BioVolume can improve repeatability, removing the reliance on a single operator to complete a study.
With 3D imaging and thermography of each rodent tumour
approach to segmentation
and measurement ensures
consistency in output.
BioVolume uses proprietary capture analysis technologies to scan rodent tumours, recording RGB, thermal and 3D model data, delivering automatic detection, segmentation and measurement of a tumour’s volume. The data is processed and stored on the BioVolume cloud, allowing for a fast capture workflow and incorporates a fully traceable data storage and output solution for detailed analysis.
HOW IT WORKS
A FAST AND INTUITIVE WORKFLOW
BioVolume was designed with the user's workflow in mind, ensuring that a measurement session can be completed as quickly as with callipers but with all the benefits of an advanced imaging platform.
INDEPENDENT ANALYSIS OF BIOVOLUME INTER-OPERATOR PERFORMANCE
In this experiment 3 operators at the Genomics Institute of the Novartis Research Foundation (GNF) were tasked with capturing measurements of subcutaneous tumours on mice with both callipers and BioVolume on the same day, for the duration of the study protocol.
This was then repeated over 2 further experiments (3 experiments in total). The primary goal was to compare the inter operator variability of the 2 techniques to see if BioVolume outperformed callipers in the repeatability of measurements between operators.
A secondary goal of the experiment was to see if collecting image data (thermal, 3D and RGB photographic image sets) using BioVolume provided additional traceability benefits to the operators.
3 Operators anonymised with labels 101, 102 and 103, were chosen at random to take measurements of single subcutaneous tumours implanted on the flank of 40 C57 Black/6 mice.
The experiment was conducted on 2 further studies containing 64 and 32 mice respectively, this time on Balb/C mice.
2 different techniques were used for measurement during this standard tumour growth study (with no compound or dosing of the animals).
12 days after implantation
GROWTH CURVE ALIGNMENT
After all of the data was collected, growth curves were plotted for both BioVolume and calliper tumour volume measurements obtained by the 3 operators.
The results can be seen in Fig. 1, and visually demonstrates reduced variability between users during the initial study, when utilising BioVolume.
Intra-class correlation analysis is used to assess the variance across operators whilst accounting for other sources of variation. High ICC corresponds to high agreement
(1 is perfect agreement).
For the 3 experiments, there is a statistically significant difference between the 2 techniques. The BioVolume ICC score is in the ‘excellent’ group, while the result for callipers falls into the ‘good/moderate’ group.
BioVolume ICC: 0.96 (0.95- 0.96)
Callipers: 0.86 (0.73 - 0.91)
Category: Good/ Moderate
DATA TRACEABILITY & VALIDATION
BioVolume records 3D models, RGB and thermal imagery for each rodent measurement, allowing interrogation at an individual rodent level. Tumour progression can be tracked visually, providing confidence in measurement output.
ICC and CoV analysis show statistically significant improvement in inter-operator variability across all 3 users when utilising BioVolume within the three individual experiments. This allows us to conclude that BioVolume can offer an improvement in study repeatability, as well as additional associated benefits.
The secondary goal of determining whether the collection of image data provided the user with additional benefits by way of allowing interrogation of raw data was also found to be true. BioVolume’s thermal, 3D and RGB image sets provided traceable visualisations of physical tumour growth over time, resulting in greater user confidence of the study outcome.
NEWS AND PUBLICATIONS
Explore the latest publications and news about BioVolume.
Modelling the cost impact of creating greater preclinical reproducibility through digitization
11/14/22, 11:58 AM
Poster presented at AALAS 2022 exploring how digitizing preclinical processes within efficacy testing, has the potential to reduce the cost of drug development by $39 million.
Re-evaluating historic preclinical endpoints with BioVolume
6/24/22, 8:10 AM
With previous experimental methods built around the limitations of calliper acquisition, we provide a method to align historical endpoints with the BioVolume platform.
Using calibrated photographic images and thermal data to investigate trends in tumour conditions
10/11/21, 10:34 AM
A poster analysing how structured image and thermal data can be used to identify trends in tumour condition in both the days leading up to, and the days following the point of ulceration.
Measurement of subcutaneous tumor height achieves greater volumetric accuracy
11/14/22, 11:58 AM
Poster presented at AALAS 2022 highlighting the need to capture tumor height for more accurate volumes.
In silico modelling demonstrates that user variability during tumor measurement can affect in vivo therapeutic efficacy outcomes
5/4/22, 7:41 AM
We show greater measurement variability results in greater experimental uncertainty, and BioVolume can reduce the chance of a false negative result.
A comparison of tumour volume accuracy taken with Callipers and BioVolume when compared to excised tumour weights
10/11/21, 10:19 AM
A poster exploring how using a BioVolume captured height measurement offers an average volume 8 times closer to the excised weight measurements than callipers.
Reducing inter-operator variability poster with GNF
11/16/20, 9:58 AM
A poster publication in partnership with GNF exploring how BioVolume can reduce inter-operator variability in measuring subcutaneous tumours
Pre-print paper: Trends in Subcutaneous Tumour Height and Impact on Measurement Accuracy
10/4/22, 9:32 AM
We show measuring tumour height is essential in calculating accurate tumour volumes, improving accuracy, reproducibility and ability to correctly identify drug effect.
Whitepaper: Modelling the economic impact of improving preclinical reproducibility with BioVolume
6/28/22, 7:48 AM
This report demonstrates how adopting BioVolume could save up to $38m in the drug development cycle, utilising the economic model created by Paul et al in their 2010 analysis.
Optimising Measurement Of Subcutaneous Rodent Leg Tumours
3/25/22, 1:51 PM
Our work with HZDR found measurement variability of rodent leg tumours can be decreased by inoculating tumour high up in the shoulder, and by using BioVolume instead of callipers.
Reducing inter-operator variability when measuring subcutaneous tumours in mice
10/11/21, 9:58 AM
Our preprint publication analysing operator variability of BioVolume vs callipers, and impact on drug efficacy assessment in over 5,000 repeats across 238 studies.
Improving reproducibility through data traceability with St. Jude Children's Research Hospital
3/9/21, 9:27 AM
Data traceability and its contribution to study reproducibility a poster in partnership with St. Jude Children's Research Hospital
Every BioVolume implementation is delivered as a complete service package including hardware, software, platform, training and support.
Scan capture button
L:278mm, H:198mm, W:169mm
USB A or C (PC) to USB B (Unit)
BioVolume Capture Application, Web based access to data via app.biovolume.com
• Thermal image • RBG Image • 3D model of tumour surface • Tumour length • Tumour width • Tumour height • Tumour Volume • Study growth curves by group / animal
• Study name • Date / Time • Operator • Animal strain • Cell line • Group • Weight • Excised weight • Comments • Segmentation adjustment
Data output format
Data output integration
Rest APi v1 Study data export
RFiD reader input, write to field weight scales
Required PC specifications
CPU: Intel i5 5th Gen RAM: 8GB
Compatible operating system
Windows 64 bit, Windows 10 Pro
Secure cloud tentant
Azure Cloud Security Compliance • Fuel3D Azure CIS 1.1.0 • Fuel3D Azure ISO 27001 • Fuel3D Azure PCI DSS 3.2.1 • Fuel3D Azure SOC TSP
Dual action capture foot pedal and adjustable stand
SUPPORT & TRAINING
Dedicated account manager
Guaranteed response timeframes from UK support team, based on issue severity
Automated additional user registration
Full hardware support for the duration of the contract
Customised user training programme
& full suite of materials